---
title: "Innovent Partner Ollin Enters Agreement to Be Acquired by Johnson & Johnson"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305716649.md"
description: "Innovent Biologics announced that its partner, Ollin Biosciences, has entered a definitive agreement to be acquired by Johnson & Johnson. Ollin's lead asset, OLN324, is a Phase 3 bispecific antibody for retinal diseases, originally discovered by Innovent and out-licensed to Ollin. Innovent stated it remains committed to advancing the program with collaborators."
datetime: "2026-11-16T14:40:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305716649.md)
  - [en](https://longbridge.com/en/news/305716649.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305716649.md)
generator: "portal-rs"
---

# Innovent Partner Ollin Enters Agreement to Be Acquired by Johnson & Johnson

Innovent Biologics ( (HK:1801) ) has issued an update.

Innovent Biologics said its partner Ollin Biosciences entered a definitive agreement to be acquired by Johnson & Johnson; Ollin’s lead program, OLN324, was discovered by Innovent and out-licensed to Ollin.

OLN324 is a Phase 3 investigational bispecific antibody targeting VEGF and Ang2 for wet age-related macular degeneration and diabetic macular edema, retinal diseases affecting more than 40 million people worldwide. Ollin has initiated patient recruitment for global Phase 3 trials, while Innovent said it remains committed to advancing the program with its collaborators.

### Related Stocks

- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [01801.HK](https://longbridge.com/en/quote/01801.HK.md)

## Related News & Research

- [UBS: Johnson & Johnson's Acquisition of Ollin Validates INNOVENT BIO  Ophthalmology R&D](https://longbridge.com/en/news/305767362.md)
- [Johnson & Johnson To Acquire Ollin Biosciences And Late-Stage Bispecific Antibody With Best-In-Class Potential In Ophthalmology](https://longbridge.com/en/news/305681892.md)
- [Johnson & Johnson looking to buy Ollin Biosciences for up to $3.4 billion, FT says](https://longbridge.com/en/news/305587733.md)
- [J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences](https://longbridge.com/en/news/305707055.md)
- [J&J - Reports Tremfya Demonstrates Mri-Confirmed Improvements In Spinal Pain And Stiffness](https://longbridge.com/en/news/306280243.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**